WO2010003862A2 - Produits antitranspirants - Google Patents

Produits antitranspirants Download PDF

Info

Publication number
WO2010003862A2
WO2010003862A2 PCT/EP2009/058267 EP2009058267W WO2010003862A2 WO 2010003862 A2 WO2010003862 A2 WO 2010003862A2 EP 2009058267 W EP2009058267 W EP 2009058267W WO 2010003862 A2 WO2010003862 A2 WO 2010003862A2
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
amino acid
application
ala
acid sequence
Prior art date
Application number
PCT/EP2009/058267
Other languages
English (en)
Other versions
WO2010003862A3 (fr
Inventor
Jean-Philippe Andre Roger Courtois
Clive Roderick Harding
Mark Harker
Iain Andrew Weddell
Original Assignee
Unilever Plc
Unilever N.V.
Hindustan Unilever Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Plc, Unilever N.V., Hindustan Unilever Limited filed Critical Unilever Plc
Publication of WO2010003862A2 publication Critical patent/WO2010003862A2/fr
Publication of WO2010003862A3 publication Critical patent/WO2010003862A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants

Definitions

  • This invention relates to the field of cosmetic products, in particular antiperspirant products. This invention also relates to methods of reducing perspiration upon the surface of the human body.
  • Cosmetic compositions used for reducing perspiration often comprise an astringent metal salt, such as aluminium or zirconium salt. Such salts reduce perspiration by blocking sweat pores. This is an effective method of reducing perspiration, but not beyond improvement. Further, not all consumers are willing to use agents that block their sweat pores.
  • the present invention utilises certain polypeptides and derivatives thereof.
  • One particular polypeptide (Tyr.Ala.Gly.Phe.Leu.) suitable for use in the present invention has previous been disclosed in WO 06/106164 (Lipotec SA).
  • a cosmetic method of reducing perspiration in the axilla comprising the application of a polypeptide or derivative thereof comprising the amino acid sequence: Tyr.Ala.Gly.Phe.Leu.
  • a cosmetic method of reducing perspiration on the feet comprising the application of a polypeptide or derivative thereof comprising the amino acid sequence: Tyr.Ala.Gly.Phe.Leu.
  • an antiperspirant product comprising a polypeptide or derivative thereof comprising the amino acid sequence: Tyr.Ala.Gly.Phe.Leu. and an astringent salt of aluminium and/or zirconium.
  • an antiperspirant product comprising a polypeptide or derivative thereof comprising the amino acid sequence: Tyr.Ala.Gly.Phe.Leu. and an anti-microbial deodorant agent.
  • a polypeptide or derivative thereof comprising the amino acid sequence: Tyr.Ala.Gly.Phe.Leu. in the manufacture of a medicament for the treatment of sweating, in particular excessive sweating or hyperhydrosis.
  • the cosmetic methods of the present invention should be understood to be non- therapeutic treatments, typically achieved by the topical application of one or more cosmetic compositions.
  • the method of controlling perspiration offered by the invention is particularly useful because the benefit can extend for a considerable period of time, often greater than 24 hours and sometimes even up to 5 days after application or longer.
  • Significant deodorancy benefits may also accrue from the use of the present invention, in particular the use of products according to the third or fourth aspect of the invention (vide supra).
  • the method of controlling perspiration and compositions according to present invention are particularly useful when direct application to the surface of the human body is involved. This is especially true when application to the axillae and/or feet is involved. Application to the axillae is most preferred because of the high concentration of eccrine sweat glands in these regions of the human body.
  • the method of controlling perspiration typically involves multiple applications of the polypeptide. It is thought that multiple applications improve perspiration reduction by some form of build up effect.
  • the composition comprising the polypeptide thereof may be applied as part of one's daily regime, after washing, for example.
  • Polypeptides suitable for use in accordance with the present invention comprise the amino acid sequence: Tyr.Ala.Gly.Phe.Leu. Other amino acids may also be present in the polypeptide, provided that they do not interrupt the above sequence. It is highly preferred that the polypeptide is water soluble (vide infra), this property enhancing delivery of the polypeptide to its site of action.
  • polypeptide is of 12 amino acid residues or less, more preferably 10 amino acid residues or less, and most preferably 8 amino acid residues or less. It has been found that longer polypeptides have at least the potential for causing undesirable responses on application to the human body.
  • polypeptides suitable for use in accordance with the present invention typically comprise the amino acid sequence:
  • polypeptide should be understood to mean “polypeptide or derivative thereof. "Derivatives thereof are typically esters, - A -
  • amides or salts.
  • Acetate esters are a particular example.
  • Certain polypeptide derivatives hydrolyse on application to yield the parent polypeptide.
  • water soluble should be understood to refer to materials having a solubility in water at 25°C of 1 g/L or greater.
  • Preferred polypeptides have a water solubility of 5g/L or greater and particularly preferred polypeptides have a water solubility of 10g/L or greater.
  • polypeptide has the amino acid sequence: Tyr.Ala.Gly.Phe.Leu. This pentapeptide is sold as the L-Tyr.D-Ala.L-Gly.L-Phe.L- Leu stereoisomer by Lipotec under the tradename Leuphasyl. ®
  • the polypeptide is preferably incorporated into a composition in an amount of from 0.0005 to 1 %, particularly from 0.001 to 0.5%, and especially from 0.005 to 0.2% by weight of the composition.
  • the polypeptide is used in conjunction with one or more further antiperspirant agents.
  • the further antiperspirant agent may enhance the antiperspirant performance of the polypeptide.
  • the polypeptide When the polypeptide is used in conjunction with a further antiperspirant agent, it is not essential that the two are part of the same composition. Independent application of the two materials may be employed. Such application may be concurrent or consecutive, provided that the treated surface experiences the presence of both materials.
  • the product When the actives are applied from independent compositions, it is preferred that the product also comprises a means for, and/or instruction for, both of the compositions to be applied to the surface requiring treatment.
  • the further antiperspirant active may be an astringent salt of aluminium and/or zirconium.
  • such an astringent salt of aluminium and/or zirconium is preferably incorporated into a composition in an amount of from 0.5- 60%, particularly from 5 to 30% or 40% and especially from 5 or 10% to 30 or 35% of the weight of the composition.
  • the ratio of the applied amount of astringent salt of aluminium and/or zirconium to the applied amount of polypeptide is preferably from 10:1 to 1000:1 and preferably 100:1 or greater.
  • Preferred astringent salts of aluminium and/or zirconium are aluminium, zirconium and aluminium/zirconium halides and halohydrate salts, such as chlorohydrates.
  • Zirconium actives can usually be represented by the empirical general formula: ZrO(OH) 2n- nzB z .wH 2 0 in which z is a variable in the range of from 0.9 to 2.0 so that the value 2n-nz is zero or positive, n is the valency of B, and B is selected from the group consisting of chloride, other halide, sulphamate, sulphate and mixtures thereof. Possible hydration to a variable extent is represented by wH 2 0. Preferable is that B represents chloride and the variable z lies in the range from 1.5 to 1.87.
  • zirconium salts may have coordinated and/or bound water in various quantities and/or may be present as polymeric species, mixtures or complexes.
  • zirconium hydroxy salts often represent a range of salts having various amounts of the hydroxy group.
  • Zirconium aluminium chlorohydrate may be particularly preferred.
  • Antiperspirant complexes based on the above-mentioned astringent aluminium and/or zirconium salts can be employed.
  • the complex often employs a compound with a carboxylate group, and advantageously this is an amino acid.
  • suitable amino acids include dl-tryptophan, dl-phenylalanine, dl- valine, dl-methionine and alanine, and preferably glycine.
  • ZAG actives generally contain aluminium, zirconium and chloride with an Al/Zr ratio in a range from 2 to 10, especially 2 to 6, an AI/CI ratio from 2.1 to 0.9 and an amount of glycine.
  • astringent aluminium and/or zirconium salt in a composition normally includes the weight of any water of hydration and any complexing agent that may also be present in the solid active. However, when the active salt is in solution, its weight excludes any water present.
  • a composition comprising an astringent salt of aluminium and/or zirconium is in the form of an emulsion the antiperspirant active will be dissolved in the disperse phase.
  • the antiperspirant active will often provide from 3 to 60% by weight of the aqueous disperse phase, particularly from 10% or 20% up to 55% or 60% of that phase.
  • a composition comprising an astringent salt of aluminium and/or zirconium may take the form of a suspension in which antiperspirant active in particulate form is suspended in the water-immiscible liquid carrier.
  • Such a composition will generally not have any separate aqueous phase present and may be referred to as "anhydrous" although it should be understood that some water may be present bound to the antiperspirant active.
  • the particle size of the antiperspirant salts often falls within the range of 0.1 to 200 ⁇ m with a mean particle size often from 3 to 20 ⁇ m.
  • a further antiperspirant agent may be a calcium channel blocking agent, as described for example in WO 02/11690 (Unilever, et al).
  • Preferred calcium channel blocking agent suitable for use as a further antiperspirant agent are magnesium salts, in particular magnesium gluconate.
  • a further antiperspirant agent may be a further polypeptide having antiperspirant activity. That is to say, the further antiperspirant agent may be a polypeptide other than one that comprises the amino acid sequence: Tyr.Ala.Gly.Phe.Leu. Suitable polypeptides are described in the following paragraphs.
  • a suitable further antiperspirant agent is a polypeptide comprising the amino acid sequence: Glu.Glu.Met.Gln.Arg.Arg.
  • Preferred polypeptides of this type have the amino acid sequences:
  • a particularly preferred polypeptides of this type has the amino acid sequence:
  • a suitable further antiperspirant agent is a polypeptide comprising the structure: ⁇ -Ala-Pro-diaminobutyroylbenzylamide.
  • a preferred polypeptide of this type has the structure ⁇ -Ala-L-Pro-diaminobutyroylbenzylamide.
  • a particular component that may enhance the antiperspirancy performance of the polypeptide is a lamellar phase stabilised oil-in-water emulsion.
  • Such emulsions are sometimes known as oleosome dispersions.
  • they comprise dispersed droplets of oil surrounded by multiple layers of liquid crystalline lamellar phase comprised of one or more surfactants.
  • the oil of the oleosome dispersions should preferably remain in a liquid state at temperatures as low as 20 0 C or even 15°C.
  • typical oils have melting point from their solid state of less than 20 0 C, preferably less than 15°C, and more preferably less than 10 0 C.
  • Preferred oils should be relatively fluid, having a kinematic viscosity of less than 100 cSt (mm 2 /s) and preferably less than 50 cSt (mm 2 /s) at 20°C.
  • Suitable oils include hydrocarbon oils and ester oils, particularly triglyceride oils, such as sunflower seed oil.
  • Other particular oils that might be used in the oleosomes are C12-15 alkyl benzoate esters, hydrogenated polybutene, PPG-14 butyl ether, thethyl citrate, isopropyl palmitate, and isopropylmyristate.
  • the lamellar phase of the oleosome dispersion is typically comprised of two non- ionic surfactants, one having a relatively low HLB (less than 8 and preferably less than 5) and one having a relatively high HLB (more than 12 and preferably more than 15).
  • the ratio high HLB surfactant to low HLB surfactant is chosen so as to give a stable oleosome dispersion, typically ratios being from 1 : 1 to 1 :6 by weight, respectively.
  • a blend of steareth-2 and steareth-20 has been found to be suitable, particularly when used in combination with sunflower oil. Steareth-2 and steareth- 20 are best used at a ratio of from 1 :4 to 1 :5 by weight.
  • the oleosome dispersions have an oil content that typically makes up from 1 to 30%, preferably from 1 to 20%, and more preferably from 1 to 10% by weight of the total composition.
  • the surfactant content typically makes up from 1 to 30%, preferably from 1 to 20%, and more preferably from 1 to 10% by weight of the composition.
  • the ratio of oil to surfactant is typically from 1 :3 to 3:1 and preferably from 1 :2 to 2:1.
  • An anti-microbial deodorant agent is a preferred additional component of compositions suitable for use in accordance with the present invention.
  • the antimicrobial deodorant agent may be a bacteriocidal agent or a bacteriostatic agent. Synergistic deodorancy benefits may be achieved using compositions comprising an anti-microbial deodorant agent.
  • Preferred anti-microbial deodorant agents are organic in nature and such antimicrobial deodorant agents are particularly preferred in compositions that do not comprise an astringent salt of aluminium and/or zirconium.
  • the anti-microbial deodorant agent is typically incorporated into the composition at from 0.01 % to 3% and particularly at from 0.03% to 0.5%.
  • Preferred anti-microbial deodorant agents have a minimum inhibitory concentration (MIC) of 1 mg.ml “1 or less, particularly 200 ⁇ g.ml "1 or less, and especially 100 ⁇ g.ml "1 or less.
  • the MIC of an anti-microbial agent is the minimum concentration of the agent required to significantly inhibit microbial growth. Inhibition is considered "significant” if an 80% or greater reduction in the growth of an inoculum of Staphylococcus epidermidis is observed, relative to a control medium without an anti-microbial agent, over a period of 16 to 24 hours at 37 0 C.
  • MICs of anti-microbials suitable for inclusion in the compositions of the invention are thclosan: 0.01 -10 ⁇ g.ml "1 (J.Regos et al., Dermatologica (1979), 158: 72-79) and farnesol: ca. 25 ⁇ g.ml "1 (K. Sawano, T. Sato, and R. Hattori, Proceedings of the 17 th IFSCC International Conference, Yokahama (1992) p.210-232).
  • ethanol and similar alkanols have MICs of greater than 1 mg.ml "1 .
  • Suitable organic anti-microbials are bactericides, for example quaternary ammonium compounds, like cetyltrimethylammonium salts; chlorhexidine and salts thereof; and diglycerol monocaprate, diglycerol monolaurate, glycerol monolaurate, and similar materials, as described in "Deodorant Ingredients", S.A.Makin and M.R.Lowry, in “Antiperspirants and Deodorants”, Ed. K. Laden (1999, Marcel Dekker, New York).
  • More preferred anti-microbials for use in the compositions of the invention are polyhexamethylene biguanide salts (also known as polyaminopropyl biguanide salts), an example being Cosmocil CQTM available from Zeneca PLC, preferably used at up to 1 % and more preferably at 0.03% to 0.3% by weight; 2',4,4'-thchloro,2-hydroxy-diphenyl ether (thclosan), preferably used at up to 1 % by weight of the composition and more preferably at 0.05-0.3%; and 3,7,11 -trimethyldodeca-2, 6,10-trienol (farnesol), preferably used at up to 1 % by weight of the composition and more preferably at up to 0.5%.
  • polyhexamethylene biguanide salts also known as polyaminopropyl biguanide salts
  • Cosmocil CQTM available from Zeneca PLC
  • transition metal chelators as described in WO01 /52805, for example.
  • Transitional metal chelators having a binding coefficient for iron(l 11) of greater than 10 26 for example diethylenetriaminepentaacetic acid and salts thereof are preferred.
  • the polypeptide may be applied to the surface of the human body by any means. Application of liquid compositions comprising the polypeptide can be by absorption onto a carrier matrix like paper, fabric, or sponge and application by contacting said carrier matrix with the surface. Application can also comprise a combination of any two or more of the above techniques.
  • compositions used in accordance with the present invention may also be present in compositions used in accordance with the present invention.
  • water may be present in a composition comprising the polypeptide.
  • the water may be considered as a carrier for the polypeptide.
  • carrier materials may alternatively or additionally be employed, provided that they are cosmetically acceptable.
  • compositions suitable for use in accordance with the invention will vary according to the desired mode of application of the composition.
  • a volatile propellant is a typical component in compositions for spray application and a liquid carrier fluid (usually water) is a typical component in compositions for roll-on application.
  • a liquid carrier fluid is a highly desirable additional component. Such materials act as solvents or carriers for the other components of the composition, facilitating their delivery.
  • Water can be used as a carrier fluid, although it is more preferable to use mixtures of water and an alcohol, especially ethanol. Alcohol/water mixtures are particularly suitable carrier fluids in roll-on and pump spray products.
  • Cyclomethicones and other volatile silicones are another class of carrier fluid that may be employed. Examples of this latter class are Dow Corning silicone fluids 344, 345, 244, 245, 246, 556, and the 200 series; Union Carbide Corp. silicones 2707 and 7158; and General Electric silicone SF1202.
  • non-silicone hydrophobic liquids may be employed, such as mineral oils, hydrogenated polyisobutene, polydecene, paraffins, isoparaffins of at least 10 carbon atoms, and aliphatic and aromatic ester iols.
  • Propylene glycol, butylene glycol, and related glycols may also be used.
  • Other alternative carrier fluids include materials having multiple functions, for example isopropyl myhstate, isopropyl palmitate, dipropylene glycol, and glycerol. Mixtures of carrier fluids may also be employed to advantage.
  • Compositions preferably comprise carrier fluid at a level of from 30% to 98% by weight, or more preferably from 60% to 97% by weight, of the nonvolatile components of the composition.
  • Emulsifiers are further additional components of the compositions of the invention that are highly desirable in certain product forms. Emulsifiers are preferably present at from 0.1 % to 10% by weight of the composition. Suitable emulsifiers include steareth-2, steareth-20, steareth-21 , ceteareth-20, glyceryl stearate, cetyl alcohol, cetearyl alcohol, PEG-20 stearate, and dimethicone copolyol.
  • perfume solubilisers and wash-off agents include PEG- hydrogenated castor oil, available from BASF in the Cremaphor RH and CO ranges, preferably present at up to 1.5% by weight, more preferably 0.3 to 0.7% by weight.
  • PEG- hydrogenated castor oil available from BASF in the Cremaphor RH and CO ranges, preferably present at up to 1.5% by weight, more preferably 0.3 to 0.7% by weight.
  • examples of the latter include poly(oxyethylene) ethers.
  • Certain sensory modifiers are further desirable components. Such materials are preferably used at a level of up to 20% by weight of the composition. Emollients, humectants, volatile oils, non-volatile oils, and particulate solids which impart lubricity are all suitable classes of sensory modifiers. Examples of such materials include cyclomethicone, dimethicone, dimethiconol, isopropyl myristate, isopropyl palmitate, talc, finely-divided silica (eg. Aerosil 200), particulate polyethylene (eg.
  • Acumist B18 polysaccharides, corn starch, C12-C15 alcohol benzoate, PPG-3 myhstyl ether, octyl dodecanol, C7-C14 isoparaffins, di-isopropyl adipate, isosorbide laurate, PPG-14 butyl ether, glycerol, hydrogenated polyisobutene, polydecene, titanium dioxide, phenyl trimethicone, dioctyl adipate, and hexamethyl disiloxane.
  • Fragrance is also a desirable additional component.
  • Suitable materials include conventional perfumes, such as perfume oils and also include so-called deo- perfumes, as described in EP 545,556 and other publications.
  • Levels of incorporation are preferably up to 4% by weight, particularly from 0.1 % to 2% by weight, and especially from 0.7% to 1.7% by weight.
  • compositions perform more than one function. Such components are particularly preferred additional ingredients, their use often saving both money and formulation space. Examples of such components include ethanol, isopropyl myristate, and the many components that can act as sensory modifiers.
  • colourants and preservatives at a conventional concentration for example C1-C3 alkyl parabens.
  • control composition used in the following Examples was a simple ethanol ic deodorant spray, lacking any antiperspirant active.
  • the composition in Table 1 was prepared using methods known in the art. The following protocol was used to evaluate this composition. Trained operators applied the composition to the axillae of panellists once each day for four consecutive days in week one and then for three consecutive days in week two (ca. 0.3g per axilla). The panellists self-applied at home at the weekend in between the two test weeks. A conventional roll-ball applicator was used for the applications. 24 hours after the last application, panellists were required to sit in a hot room (temperature: 4O 0 C; relative humidity: 40%) for up to one hour and twenty minutes. A further hot room sitting with the same conditions followed 96 hours after the last application, panellists being allowed wash as normal in the intervening period. During the sittings, sweat was collected on absorbent cotton pads held in each axilla, Example 1 having been applied to one axilla and a control composition lacking antiperspirant agent to the other.
  • This amount refers to the 0.05% aqueous solution of Leuphasyl ® supplied by Lipotec. Hence, the actual amount of polypeptide present in the composition was 0.005%. Sunflower seed oil.
  • composition of Table 1 A significant antiperspirancy benefit resulted from application of the composition of Table 1. Relative to the control formulation, a sweat weight reduction (SWR) of approximately 25% was observed in the first hot room sitting and there was still an observable benefit (18% SWR) in the second hot room sitting, after the 4 day “wash out” period.
  • SWR sweat weight reduction
  • the cosmetic compositions indicated in Table 2 may be prepared using methods known in the art. It will be noted that the compositions comprising both the peptide and an anti-microbial can deliver both significant antiperspirancy and significant deodorancy.

Abstract

L'invention concerne un procédé de réduction de la transpiration comprenant l'application d'un polypeptide ou d'un de ses dérivés comprenant la séquence d'acides aminés Tyr.Ala.Gly.Phe.Leu.
PCT/EP2009/058267 2008-07-08 2009-07-01 Produits antitranspirants WO2010003862A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08159876.5 2008-07-08
EP08159876 2008-07-08

Publications (2)

Publication Number Publication Date
WO2010003862A2 true WO2010003862A2 (fr) 2010-01-14
WO2010003862A3 WO2010003862A3 (fr) 2011-03-17

Family

ID=40090086

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/058267 WO2010003862A2 (fr) 2008-07-08 2009-07-01 Produits antitranspirants

Country Status (2)

Country Link
AR (1) AR072719A1 (fr)
WO (1) WO2010003862A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2961508A1 (fr) * 2010-06-17 2011-12-23 Oreal Derives d'acide amine ; compositions les contenant ; utilisation comme agent de traitement de la transpiration humaine
FR2961510A1 (fr) * 2010-06-17 2011-12-23 Oreal Utilisation comme agent de traitement de la transpiration humaine ; nouveaux derives d'acide amine ; compositions les contenant
FR2961509A1 (fr) * 2010-06-17 2011-12-23 Oreal Derives d'acide amine ; compositions les contenant ; utilisation comme agent de traitement de la transpiration humaine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523812A (en) * 1976-04-08 1978-09-06 Ici Ltd Polypeptide
FR2735687A1 (fr) * 1995-06-21 1996-12-27 Sederma Sa Nouvelles compositions cosmetiques amincissantes
US5788956A (en) * 1995-10-26 1998-08-04 Societe L'oreal S.A. Antiperspirant compositions comprising substance P antagonists
US20080107679A1 (en) * 2003-08-14 2008-05-08 Natalie Dilallo Skin care compositions including hexapeptide complexes and methods of their manufacture

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523812A (en) * 1976-04-08 1978-09-06 Ici Ltd Polypeptide
FR2735687A1 (fr) * 1995-06-21 1996-12-27 Sederma Sa Nouvelles compositions cosmetiques amincissantes
US5788956A (en) * 1995-10-26 1998-08-04 Societe L'oreal S.A. Antiperspirant compositions comprising substance P antagonists
US20080107679A1 (en) * 2003-08-14 2008-05-08 Natalie Dilallo Skin care compositions including hexapeptide complexes and methods of their manufacture

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2961508A1 (fr) * 2010-06-17 2011-12-23 Oreal Derives d'acide amine ; compositions les contenant ; utilisation comme agent de traitement de la transpiration humaine
FR2961510A1 (fr) * 2010-06-17 2011-12-23 Oreal Utilisation comme agent de traitement de la transpiration humaine ; nouveaux derives d'acide amine ; compositions les contenant
FR2961509A1 (fr) * 2010-06-17 2011-12-23 Oreal Derives d'acide amine ; compositions les contenant ; utilisation comme agent de traitement de la transpiration humaine
WO2011157610A3 (fr) * 2010-06-17 2012-03-29 L'oreal Utilisation de nouveaux dérivés d'acides aminés comme agents pour traiter la transpiration chez l'humain et compositions contenant ces dérivés
WO2011157611A3 (fr) * 2010-06-17 2012-06-28 L'oreal Dérivés d'acides aminés, compositions contenant ces dérivés et utilisation comme agents pour traiter la transpiration chez l'humain
WO2011157612A3 (fr) * 2010-06-17 2012-06-28 L'oreal Dérivés d'acides aminés, compositions contenant ces dérivés et utilisation comme agents pour traiter la transpiration chez l'humain

Also Published As

Publication number Publication date
WO2010003862A3 (fr) 2011-03-17
AR072719A1 (es) 2010-09-15

Similar Documents

Publication Publication Date Title
WO2010003861A1 (fr) Produits anti-transpiration
WO2010003828A2 (fr) Produits antiperspirants
WO2010003781A1 (fr) Compositions anti-transpiration
CA2350694C (fr) Compositions antisudorales et deodorantes faiblement irritantes
EP1416910B1 (fr) Compositions d'application topique renfermant des derives selectionnes de l'acide pantothenique
US20050191255A1 (en) Anti-microbial antiperspirant products
MXPA06014680A (es) Composiciones antitranspirantes que comprenden ozoquerita.
AU5467199A (en) Antiperspirant compositions containing calcium salts
JP2004517093A (ja) 制汗製品
US6509010B2 (en) Cosmetic products for the reduction of sweat acidity
EP2442779B1 (fr) Utilisation anti-transpirante
WO2010003862A2 (fr) Produits antitranspirants
EP3866935B1 (fr) Procédé de réduction de la transpiration
EP3233024B1 (fr) Compositions antitranspirantes comprenant des aluns
WO2023117442A1 (fr) Composition antitranspirante
WO2022122884A1 (fr) Composition antitranspirante
US20240082126A1 (en) An anhydrous antiperspirant composition
WO2024061537A1 (fr) Composition cosmétique
WO2022167211A1 (fr) Composition anti-transpirante anhydre
EP3493786A1 (fr) Agent actif et procédé pour réduire les mauvaises odeurs

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09780060

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09780060

Country of ref document: EP

Kind code of ref document: A2